The Federal Trade Commission (FTC) issued a report May 21, 2008 summarizing agreements filed with the FTC in FY 2007 by generic and branded drug manufacturers, as mandated by the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. During this period, there were 33 final settlements, nearly half of which included both compensation to the generic company (such as through an agreement by the branded firm not to sponsor or compete with an authorized generic product for some period of time) and a restriction on the generic’s ability to market its product.